NMS Group
Tiziano Andreoli has a diverse work experience, with their most recent role being the CIO at NMS Group since March 2020. Prior to that, they were an IT Director at MolMed Spa from January 2016 to February 2020, where they focused on ensuring compliance with company and pharma policies and collaborated with various teams for organization's performance targets. From May 2008 to December 2015, they worked as an IT Manager at Molmed Spa and Phoenix Int. Spa, where they developed technical procedures, led teams for ERP infrastructure management, and performed software analysis and development. Before that, Tiziano was the R&D Manager at Phoenix International Spa, handling tools analysis, design, and development, collaborating with cross-functional teams and directing staff training in R&D and IT subjects.
Tiziano Andreoli has a Bachelor's degree in Electronic Engineering with a focus on Industrial Automation, which they obtained from Università degli Studi di Brescia from 1995 to 2001. Prior to that, they earned an Industrial Technician Diploma in Information Technology from Istituto "Benedetto Castelli" in Brescia, which they completed between 1989 and 1994. Additionally, Tiziano Andreoli obtained a CISM ISACA certification from ISACA in January 2018.
This person is not in any teams
NMS Group
NMS Group S.p.A. is the largest company in Italy committed in innovation and oncology R&D. With 420 total employees, NMS Group employs over 200 qualified researchers involved in research and development, from 'target validation' to phase II clinical trials. NMS Group S.p.A. is the only company in Italy able to manage the entire integrated chain of the research and development path: from pre-clinical phase of research, to First-Time-In-Man of clinical phase, up to production and packaging of the finished drug. The Group also provides services of Research and Production addressed to local and international markets through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.